Ireland's GH Research Q1 net loss widens on higher expenses

GH Research

14/05/2026 12:16

Overview

Ireland biopharma firm's Q1 net loss widened yr/yr on higher R&D and admin expenses

Company ended Q1 with $267.3 mln cash, raised $111.2 mln more in April

Result Drivers

R&D SPENDING - Higher research and development expenses due to increased technical and clinical development activity, as well as employee costs

ADMIN COSTS - General and administrative expenses rose mainly due to higher professional fees

Company press release: ID:nGNX4XbpFC

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.31


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for GH Research PLC is $36.50, about 66.8% above its May 13 closing price of $21.88

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)